# Progress Note 05 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Zelda Fitzgerald (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ET004-SYN
- Date: 2026-08-10
- Fictional facility: St. Posthumous Health Center
- Fictional author: Margot Ellery, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Three-month review: lithium, thyroid, kidney and metabolic checks, and the diagnosis reviewed. **S**

## History of present illness

Ms. Fitzgerald returns three months after her first visit, fasting for her blood tests. She stopped risperidone eight weeks ago and takes aripiprazole 10 mg each morning and lithium 300 mg twice daily. She had a few days of mild inner restlessness in the first week of the switch, which passed. Her period returned in mid-July, five weeks after the switch, and again this month. She has had no manic, depressive, or psychotic symptoms since the spring and sleeps eight hours. She dances about three hours a day and eats to the dietitian's plan. Since the last visit, with her consent, her roommate and her own journal have filled in the weeks before the admission: the sleeplessness, rapid speech and grand plans came first, for about three weeks, and the voice and the belief she was being watched began only in the last week before admission and ended with the mania. She has had no thoughts of suicide or self-harm. **S**

| Element | Detail |
|---|---|
| Medicines | Lithium 300 mg twice daily; aripiprazole 10 mg daily; risperidone stopped eight weeks ago |
| Periods | Returned in mid-July; regular since |
| Course of the episode | Manic symptoms for about three weeks before any psychotic symptoms, which ended with them |
| Mood | Steady; PHQ-9 4; item 9 scored 0 |
| Dance | About three hours a day, eating to plan |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Energy good; weight up 1.4 kg, as planned |
| Genitourinary | Negative | Periods regular since July; no increased urination |
| Endocrine | Negative | No thirst, heat or cold intolerance, or breast discharge |
| Neurological | Negative | Restlessness in the first week of the switch resolved; faint tremor when tired |
| Psychiatric | Negative | Mood steady; no manic or psychotic symptoms; no thoughts of suicide or self-harm |

5 systems reviewed. **S**

## Current medications

- Lithium carbonate 300 mg oral capsule, one capsule by mouth twice daily **S**
- Aripiprazole 10 mg oral tablet, one tablet by mouth once daily **S**

## Allergies

- No known allergy **S**

## Objective

BP 108/68 mmHg; pulse 70 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 99% on room air; weight 51.6 kg; BMI 19 kg/m². All vital signs are synthetic.

Sodium: 140 mmol/L; Potassium: 4.2 mmol/L; Creatinine: 0.8 mg/dL; eGFR: 102 mL/min/1.73 m²; Lithium (12-hour trough): 0.74 mmol/L; TSH: 2.9 mIU/L; Calcium: 9.6 mg/dL; Prolactin: 14 ng/mL; Fasting glucose: 86 mg/dL; Hemoglobin A1c: 5.1%; Total cholesterol: 174 mg/dL; LDL cholesterol: 94 mg/dL; HDL cholesterol: 62 mg/dL; Triglycerides: 82 mg/dL; PHQ-9: 4. All results are synthetic.

## Change since baseline

- Sodium: 139 mmol/L at baseline, 140 mmol/L at this visit **S**
- Potassium: 4 mmol/L at baseline, 4.2 mmol/L at this visit **S**
- Creatinine: 0.72 mg/dL at baseline, 0.8 mg/dL at this visit **S**
- eGFR: 116 mL/min/1.73 m² at baseline, 102 mL/min/1.73 m² at this visit **S**
- TSH: 2.1 mIU/L at baseline, 2.9 mIU/L at this visit **S**
- Calcium: 9.4 mg/dL at baseline, 9.6 mg/dL at this visit **S**
- Prolactin: 62 ng/mL (high) at baseline, 14 ng/mL at this visit **S**
- Hemoglobin A1c: 5% at baseline, 5.1% at this visit **S**
- Total cholesterol: 168 mg/dL at baseline, 174 mg/dL at this visit **S**
- LDL cholesterol: 90 mg/dL at baseline, 94 mg/dL at this visit **S**
- HDL cholesterol: 64 mg/dL at baseline, 62 mg/dL at this visit **S**
- Triglycerides: 70 mg/dL at baseline, 82 mg/dL at this visit **S**
- PHQ-9: 11 at baseline, 4 at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; weight 51.6 kg, BMI 19.0; blood pressure 108/68, pulse 70 |
| Neck | Thyroid not enlarged |
| Neurological | Faint fine postural tremor; no akathisia, rigidity, or abnormal movements |
| Psychiatric | Euthymic; organized; no psychotic or manic features |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Bipolar I disorder with psychotic features, in full remission** (F31.74). The course now settles the provisional diagnosis. The psychotic symptoms occurred only within a manic episode and ended with it, which fits bipolar I disorder with psychotic features rather than schizoaffective disorder, which needs psychosis for two weeks or more without mood symptoms, or schizophrenia. Mood has been normal for about two months, so the illness is in full remission. The label will be revised if psychosis ever occurs apart from a mood episode. Lithium 0.74 mmol/L; creatinine 0.80 mg/dL, eGFR 102; TSH 2.9 mIU/L; calcium 9.6 mg/dL. The 12-week metabolic check is normal: fasting glucose 86 mg/dL, A1c 5.1%, total cholesterol 174, LDL 94, HDL 62 and triglycerides 82 mg/dL. Dr. Langford reviewed the history by phone and agrees. Safety reviewed: no thoughts of suicide or self-harm; the safety plan is current. **S**
   - Continue lithium carbonate 300 mg twice daily and aripiprazole 10 mg daily.
   - Lithium level, creatinine and TSH again at six months.
   - Pregnancy planning: lithium carries a small added risk of heart defects early in pregnancy, valproate is avoided, and any pregnancy should be planned with psychiatry; she would like a long-acting method placed at the preventive visit.
2. **First episode of psychosis with marked mood symptoms** (F29). Superseded by the diagnosis of bipolar I disorder with psychotic features. **S**
   - Problem resolved.
3. **Secondary amenorrhea** (N91.1). Resolved: prolactin 14 ng/mL on aripiprazole, periods regular, and energy intake matched to training. **S**
   - Keep the dietitian's plan as training increases; report any missed period.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Medication safety | Antipsychotic dose, adherence, and response | Every visit | Completed today | Aripiprazole 10 mg for eight weeks; full adherence; in remission |
| Survey | Manic, depressive, and psychotic symptoms, and early warning signs | Every visit | Completed today | No manic, depressive, or psychotic symptoms; the history of the episode clarified |
| Examination | Akathisia, parkinsonism, and sedation | Every visit in the first months and after any dose change | Completed today | Mild restlessness in the first week of the switch, resolved; none now |
| Examination | Weight and BMI | Every visit for 6 months after starting or changing an antipsychotic (CMID: baseline, 4, 8, and 12 weeks, then quarterly) | Deferred | 51.6 kg (BMI 19.0) today, up 1.4 kg since the switch, as she and the dietitian planned. The weight check due four weeks after the switch to aripiprazole was missed because no visit fell then; no harm resulted, since the gain was intended and modest. Corrective action: the care coordinator records her weight at the monthly meeting until six months after the switch |
| Examination | Blood pressure | Baseline, 12 weeks, then yearly | Completed today | 108/68 |
| Laboratory | Fasting glucose and A1c | Baseline, 12 weeks to 4 months, then yearly | Completed today | Fasting glucose 86 mg/dL; A1c 5.1%; sixteen weeks after the antipsychotic was started, within the APA's four months; yearly from now |
| Laboratory | Fasting lipid panel | Baseline, 12 weeks to 4 months, then yearly | Completed today | Total cholesterol 174, LDL 94, HDL 62, triglycerides 82 mg/dL; yearly from now |
| Laboratory | Prolactin | When there are symptoms of high prolactin, such as missed periods | Completed today | 14 ng/mL, normal, eight weeks after the switch; periods back |
| Laboratory | Lithium level (12-hour trough) | 5 to 7 days after starting and after any change until stable, then every 3 to 6 months | Completed today | 0.74 mmol/L |
| Laboratory | Creatinine and eGFR on lithium | Baseline, every 2 to 3 months for 6 months, then every 6 to 12 months | Completed today | Creatinine 0.80 mg/dL, eGFR 102; sodium 140, potassium 4.2 mmol/L |
| Laboratory | TSH on lithium | Baseline, once or twice in the first 6 months, then every 6 to 12 months | Completed today | 2.9 mIU/L, from 2.1 |
| Laboratory | Calcium on lithium | Baseline, then yearly | Completed today | 9.6 mg/dL; yearly from now |
| Medication safety | Lithium side effects and sick-day rules | At the start and every visit | Completed today | Faint tremor only; no thirst or increased urination |
| Medication safety | Pregnancy prevention on lithium; valproate avoided | Before starting and at each visit until a reliable method is in place | Completed today | Counseling repeated; she chose a levonorgestrel intrauterine system at the preventive visit |
| Survey | Depression measure (PHQ-9) | Monthly during acute treatment, every 2 to 4 weeks in continuation, then periodically | Completed today | PHQ-9 4, item 9 scored 0; the care coordinator's monthly check between visits was in the low range |
| Survey | Suicide-risk review, safety plan, lethal means, and the 988 Suicide & Crisis Lifeline | Every visit | Completed today | No thoughts of suicide or self-harm; safety plan current |
| Self-management | Sleep | Every visit | Completed today | Eight hours at regular times |
| Self-management | Eating, exercise, and periods | Every visit while periods are absent or weight is low | Completed today | Periods regular; dancing about three hours a day; eating to plan |
| Self-management | Coordinated specialty care engagement | Ongoing, for up to two to three years | Completed today | Therapist every two weeks; peer specialist monthly; writing and dancing again |

## Goal progress

- No manic, depressive or psychotic episode and no readmission through six months. In progress; target 2026-10-26. **S**
- Lithium trough level 0.6 to 0.8 mmol/L with normal kidney and thyroid tests at six months. In progress; target 2026-10-26. **S**
- Periods return and prolactin is normal by three months. Outcome by 2026-08-10: Periods returned five weeks after the switch to aripiprazole; prolactin 14 ng/mL. **S**
- BMI at least 19, with food matched to her training, by six months. In progress; target 2026-10-26. **S**
- PHQ-9 score below 5 by six months. In progress; target 2026-10-26. **S**

## Guideline basis

- Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder (2018), CANMAT and ISBD (Bipolar Disorders)
- The CANMAT and ISBD Guidelines for the Treatment of Bipolar Disorder: Summary and a 2023 Update of Evidence (2023), Focus (American Psychiatric Publishing)
- The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia, Third Edition (2020), American Psychiatric Association (American Journal of Psychiatry)
- Consensus development conference on antipsychotic drugs and obesity and diabetes (2004), American Diabetes Association, American Psychiatric Association, AACE, and NAASO (Diabetes Care)
- Recovery After an Initial Schizophrenia Episode (RAISE): coordinated specialty care for first-episode psychosis (2026), National Institute of Mental Health
- U.S. Selected Practice Recommendations for Contraceptive Use, 2024 (2024), Centers for Disease Control and Prevention (MMWR Recommendations and Reports)
- VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024), United States Department of Veterans Affairs and Department of Defense
- CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026), Aether Forge

## Follow-up

- Preventive visit in five weeks for a long-acting contraceptive. Six-month review with lithium level, creatinine, TSH, and the AIMS. Care coordinator monthly. **S**
- Next scheduled visit 2026-09-14: periodic adult preventive visit with contraception. **S**
